PT  - JOURNAL ARTICLE
AU  - Sunjay Kaushal
AU  - Jessica R Hoffman
AU  - Riley M Boyd
AU  - Joshua M Hare
AU  - Kevin N. Ramdas
AU  - Nicholas Pietris
AU  - Shelby Kutty
AU  - James S Tweddell
AU  - S. Adil Husain
AU  - Shaji C. Menon
AU  - Linda M. Lambert
AU  - David A Danford
AU  - Seth J Kligerman
AU  - Narutoshi Hibino
AU  - Laxminarayana Korutla
AU  - Prashanth Vallabhajosyula
AU  - Michael J. Campbell
AU  - Aisha Khan
AU  - Keyvan Yousefi
AU  - Danial Mehranfard
AU  - Lisa McClain-Moss
AU  - Anthony A. Oliva
AU  - Michael E Davis
TI  - Intramyocardial cell-based therapy during bidirectional cavopulmonary anastomosis for hypoplastic left heart syndrome: The ELPIS phase I trial
AID  - 10.1101/2022.08.04.22278321
DP  - 2022 Jan 01
TA  - medRxiv
PG  - 2022.08.04.22278321
4099  - http://medrxiv.org/content/early/2022/08/09/2022.08.04.22278321.short
4100  - http://medrxiv.org/content/early/2022/08/09/2022.08.04.22278321.full
AB  - Background Hypoplastic left heart syndrome (HLHS) survival relies on surgical reconstruction for the right ventricle (RV) to provide systemic circulation. This leads to substantially increased loads on the RV, wall stress, maladaptive remodeling and dysfunction, which in turn can increase risk of death or transplantation.Objectives We conducted a phase I multicenter trial to assess safety and feasibility of intra-operative MSC injection in HLHS patients to boost RV performance in the systemic position.Methods Allogeneic MSCs were directly administered by intramyocardial injections during the second stage palliative operation. The primary endpoint was safety.Results Ten patients received intramyocardial injections of allogeneic MSCs (Lomecel-B). No patients experienced major adverse cardiac events (MACE). All subjects were alive and transplant-free at 1 year following, and experienced growth comparable to healthy control historical data. Cardiac magnetic resonance imaging (CMR) revealed improving tricuspid regurgitant fraction (Baseline: 0.45±0.19; 6 mo.: 0.32±0.06; 12 mo.: 0.06±0.09), while global longitudinal strain (Baseline: -24.39±6.99; 6 mo.: -20.55±3.05, p > 0.05 vs baseline; 12 mo.: - 23.88±4.6, p>0.05 vs baseline) and RV ejection fraction (EF; baseline: 62.62±5.99; 6 mo.: 53.69±9.56; 12 mo.: 52.31±5.63: p=NS for change over time) were unchanged. Computational modeling identified 167 derived RNAs specific to circulating exosomes originating from transplanted MSCs corresponding to RVEF changes and identifying potential mechanistic underpinnings.Conclusions Intramyocardial MSCs appear safe in HLHS patients, and may favorably affect RV performance. Circulating exosomes of transplanted MSC-specific provide novel insight into bioactivity. Conduct of a controlled phase trial is warranted and is underway.Condensed Abstract The ELPIS phase I trial was designed to assess safety and feasibility of intramyocardial injection of allogeneic MSCs into the RV during second stage palliation of HLHS. There were no incidences of major adverse cardiac events (MACE) or other safety concerns, and there was a 100% transplant-free survival at 1-year follow-up, supporting the safety and feasibility of this approach. The ELPIS results are important for advancing MSC therapy for all ages and congenital heart conditions, and warrant further investigation in a controlled Phase II trial powered for efficacy.Competing Interest StatementJ.M.H. is a stockholder in Vestion, Inc., Heart Genomics, and Longeveron, Inc. J.M.H. is the Chief Scientific Officer, a compensated consultant and board member for Longeveron, and holds equity in Longeveron. J.M.H. is also the co-inventor of intellectual property licensed to Longeveron. Dr. Hare's relationships are disclosed to the University of Miami, and a management plan is in place. S.K. is a founder of Neoprogen, Inc. The University of Miami is an equity owner in Longeveron, which has licensed intellectual property from the University of Miami. K.N.R., K.Y., D.M., L.M., and A.A.O. are full-time employees of Longeveron Inc.Clinical TrialNCT03525418 and NCT02398604Funding StatementThe ELPIS trial is funded through the Maryland Stem Cell Research Fund (MSCRF) grant #2017-MSCRFCL-3955, Children's Heart Foundation. S.K. is funded by grants from the National Institutes of Health (NIH)/National Heart, Lung, and Blood Institute (R01HL118491, R01 HL139060-01A1, R42HL131226-01); and Moseley Foundation. J.M.H. is funded by grants from the NIH/National Heart, Lung, and Blood Institute (R01 HL107110, 1R01HL134558-01, 4R01HL084275-10, 5R01HL116899-04, and HHSN268201600012I); NIH/National Cancer Institute (5R01CA136387-07); Soffer Foundation; Marcus Foundation, and Starr Foundation. M.S. is funded by NIH grant K08HL146351. A.A.O. is funded by grants from the National Institutes of Health (NIH)/National Institute on Aging, the MSCRF, and Alzheimer's Association. M.E.D. is funded by grants from the NIH/National Heart, Lung, and Blood Institute (R01HL145644) and through the Marcus Foundation.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was under the oversight of an independent Institutional Review Board (Western IRB: Puyallup, WA) and Data Safety Monitoring Board (DSMB). The consent form, protocol, and all supporting documents were also reviewed by the IRBs of participating centers: University Maryland Medical Center, Cincinnati Children's Hospital Medical Center, and Primary Children's Medical Center.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors